go-v.orgdoi

Role of p53 Family Proteins in Metformin Anti-Cancer Activities

Yong Yi, Wenhua Zhang, Jianqiao Yi, Zhi‐Xiong Jim Xiao · Journal of Cancer · 2019

  • DOI 10.7150/jca.30659
  • Publisher Ivyspring International Publisher
  • Type review
  • Issued 2019

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · review · 2019

Abstract

Metformin has been used as therapy for type 2 diabetes for many years. Clinical and basic evidence as indicated that metformin has anti-cancer activities. It has been well-established that metformin activates AMP-activated protein kinase (AMPK), which in turn regulates energy homeostasis. However, the mechanistic aspects of metformin anti-cancer activity remain elusive. p53 family proteins, including p53, p63 and p73, have diverse biological functions, including regulation of cell growth, survival, development, senescence and aging. In this review, we highlight the evidence and mechanisms by which metformin inhibits cancer cell survival and tumor growth.

We also aimed to discuss the role of p53 family proteins in metformin-mediated suppression of cancer growth and survival.

Open the resolved locator · 10.7150/jca.30659

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:17 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v10p2434.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.